Hybridon is engaged in the discovery, development and commercialization of novel therapeutics based on synthetic DNA for the treatment of cancer, asthma and allergies, and infectious diseases. The company's drug candidates are designed to modulate immune responses through Toll-like receptor 9 and antisense. Its discovery platforms to identify drug candidates are based on DNA chemistries developed at Hybridon. The company, founded by the Worcester Foundation for Biomedical Research, was incorporated in 1989 for the purpose of engaging in the discovery and development of novel therapeutics through the application of synthetic DNA. Headquartered in Cambridge, Mass., Hybridon is a publicly owned company that employs nearly 30 people.